Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track?
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: August 20, 2015
Expiration Date: August 20, 2016
Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.
The vast majority of patients with pancreatic cancer present with disease which is either metastatic or locally advanced inoperable. At that point, systemic therapy becomes the mainstay of care. Over the past several years, the standard of care has been a gemcitabine based regimen. Most recently, two positive phase 3 trial results have led to a shift in the way patients with advanced metastatic pancreatic cancer are treated. With additional ongoing trials and the promise of additional treatment options on the horizon it is important for community oncologists to be educated about these emerging treatments so that they can deliver optimal care to their patients.
This activity is designed for oncologists, pharmacists, and associated multidisciplinary clinical specialists who provide care to patients with pancreatic cancer.
Upon completion of this educational activity, participants should be able to:
- Outline current therapeutic options for first-line treatment for advanced metastatic pancreatic cancer including efficacy and safety data
- Summarize recent clinical trial data of novel and investigational agents for the treatment of first-line and second-line treatment of patients with metastatic pancreatic cancer
Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track? Andrew H. Ko, MD, and Tanios Bekaii-Saab, MD
Instructions for Participation and Credit
This activity is eligible for credit through August 20, 2016. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Andrew H. Ko, MD
Associate Professor of Clinical Medicine
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California
Dr. Andrew Ko received his medical degree from Johns Hopkins School of Medicine. He completed his internship and residency in internal medicine at Beth Israel Hospital/Harvard Medical School and his fellowship in medical oncology at Stanford University School of Medicine. He is currently associate professor of clinical medicine, Department of Medicine at the University of California, San Francisco (UCSF).
Dr. Ko is board certified in internal medicine and medical oncology. He is on the Board of Directors of the Association of Northern California Oncologists and holds memberships in the Massachusetts Medical Society, American Society of Clinical Oncology (ASCO), American Association for Cancer Research, Cancer and Leukemia Group B (CALGB), Pancreatic Cancer Task Force/National Cancer Institute (NCI), and National Comprehensive Cancer Network (NCCN)/Pancreatic Adenocarcinoma Panel. In addition, Dr. Ko is an ad hoc referee for Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, The New England Journal of Medicine, Lancet Oncology, Investigational New Drugs, Molecular Cancer Therapeutics, British Journal of Cancer, Expert Opinion on Pharmacotherapy, Journal of Molecular Medicine, American Journal of Cancer, and World Journal of Surgical Oncology, and is on the editorial board of People Living With Cancer (ASCO),The Oncologist, HemOnc Today, and the Journal of Clinical Oncology. Dr. Ko’s areas of interest include gastrointestinal malignancies (pancreatic cancer, colorectal cancer, esophageal cancer, gastric cancer, hepatocellular cancer, anal cancer, neuroendocrine tumors), clinical trials, molecular predictors, biologic therapy, targeted therapy, investigational new agents, and circulating tumor cells.
Tanios Bekaii-Saab, MD
Chief, Section of Gastrointestinal Oncology
Chair, CCC Gastrointestinal Disease Research Group
Professor of Medicine and Pharmacy
The Ohio State University – James Cancer Hospital
Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab is a tenured associate professor of medicine and pharmacology and section chief for the gastrointestinal cancer program at The Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute. He is also the chairman of the disease specific research group for the comprehensive cancer center.
Dr. Bekaii-Saab is actively involved in a number of professional societies including the American Society of Clinical Oncology, American Association for Cancer Research, American Society for Clinical Pharmacology and Therapeutics, and the Alliance cooperative group. He also serves as a member on the Colorectal Cancer Panel for NCCN. In addition, he has served as a reviewer for over 50 journals, as journal editorial board member of JNCCN, World Journal of Hepatology, US Oncological Review, and HemOnc Today, and has authored more than 100 publications and 130 abstracts in a number of journals including Journal of Clinical Oncology, Annals of Oncology, and Clinical Cancer Research.
Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on gastrointestinal malignancies, and molecular targeted and immune therapies. He is the principal investigator on numerous clinical trials and the recipient of numerous research grants. Dr. Bekaii-Saab is also the recipient of the prestigious NCI clinical investigator team leadership award and the ASCO leadership program development award. Additionally, he has been listed in U.S. News and World Report’s Top Doctors and is one of the Best Doctors in America.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-053-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Andrew Ko has received honoraria related to formal advisory activities from ARMO BioSciences, Halozyme, Inc., Merrimack Pharmaceuticals, Inc., as well as consultant fees from Incyte Corporation. He has received grant support related to research activities from Acerta Pharma, Aduro Biotech, Genentech, Inc., Infinity Pharmaceuticals, Merck & Co., Inc., Merrimack, OncoGenex Pharmaceuticals Inc., and PRISM BioLab Co., Ltd.
Dr. Tanios Bekaii-Saab has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb, Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Genentech, Inc., Merrimack Pharmaceuticals, Inc., and Pfizer Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Ko has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Bekaii-Saab has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Ko and Dr. Bekaii-Saab have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Aduro BioTech.
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.